References
1. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998. 39Suppl 7. S22–S26.
2. Asconape JJ. Some common issues in the use of anti-epileptic drugs. Semin Neurol 2002. 2227–39.
3. Sussman NM, McLain LW Jr. A direct hepatotoxic effect of valproic acid. JAMA 1979. 2421173–1174.
4. Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities III US experience since 1986. Neurology 1996. 46465–469.
5. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987. 37379–385.
6. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987. 28Suppl 3. S64–S70.
7. Pellock JM. In : Willmore LJ, ed. Felbamate. New antiepileptic drugs: basic and clinical use in children and adults. American Epilepsy Society annual course 1998. 12. 06. San Diego: H1–H13.
8. Hawkins CF, Meynell MJ. Macrocytosis and macrocytic anaemia caused by anticonvulsant drugs. Q J Med 1958. 2745–63.
9. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Mayersdorf A, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985. 313145–151.
10. Browne TR. In : Engel JJ, Pedley TA, eds. Phenytoin and other hydantoins. Epilepsy: comprehensive textbook 1997. Philadelphia: Lippincott-Raven Publishers; 1557–1579.
11. Verrotti A, Greco R, Matera V, Altobelli E, Morgese G, Chiarelli F. Platelet count and function in children receiving sodium valproate. Pediatr Neurol 1999. 21611–614.
12. Gidal B, Spencer N, Maly M, Pitterle M, Williams E, Jones J, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994. 441418–1422.
13. Gilhus NE, Matre R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurol Scand 1986. 74181–185.
14. Livingston S, Villamater C, Sakata Y, Pauli LL. Use of carbamazepine in epilepsy. Results in 87 patients. JAMA 1967. 200204–208.
15. Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol 1982. 11309–312.
16. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997. 381265–1269.
17. Kälviäinen R, Nousiainen I, Mantijarvi M. Initial vigabatrin monotherapy is associated with increased risk of visual field constriction: a comparative follow-up study with patients on initial carbamazepine monotherapy and healthy control. Epilepsia 1989. 3972.
18. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996. 37Suppl 2. S18–S22.
19. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993. 3291383–1388.
20. Roos KL, Flippern CC II, Hingtgen C, Markand ON, Hattson DH, Wojcieszek J, et al. Neurologic disorders and pregnancy. Continnum: Lifelong learning in neurology 2000. 8–63.